2 results
Approved WMOWill not start
PRIMARY• To determine the efficacy on study Day 28 of the IT-combination in inducing a clinical response in patients with severe acute GVHD refractory to first line therapy with intermediate dose corticosteroids. SECONDARY• To evaluate the overall…
Approved WMOWill not start
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…